Group items tagged

Policy Report\n\nLearn more about the new WCRF/AICR report, Policy and Action for Cancer Prevention, which was launched at an international press briefing in London at 10 a.m. GMT (5 a.m. US Eastern Time), and presented to US lawmakers at a Congressional Briefing at 10 a.m. US Eastern Time, on February 26th, 2009.

For the first time, medical groups have issued guidelines that say healthy older men should consider taking a drug that may reduce their risk of developing prostate cancer, even if they're just among the worried well who go in for regular screenings.\n\nThe drug, finasteride, is already used to treat male pattern baldness and to shrink enlarged prostates. The new guidelines suggest that patients who are already taking finasteride for those conditions or who go for regular prostate cancer screening tests should discuss long-term treatment with the drug with their doctors.

Not enough vitamin D: health consequences for Canadians.\nSchwalfenberg G.\nCan Fam Physician. 2007 May;53(5):841-54. Review.\nPMID: 17872747 \n

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.\nMichelakis ED, Webster L, Mackey JR.\nBr J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review.\nPMID: 18766181 \ndoi:10.1038/sj.bjc.6604554 \n

Whether you're deciding on brachytherapy or are interested in nutraceuticals and diet, Prostate Forum tackles the latest on prostate cancer and beyond, responding with timely information for men of any age or at any stage of treatment.\n\nDr. Myers answer

C. Cox, S. D. Merajver, S. Yoo, R. D. Dick, G. J. Brewer, J. S.-J. Lee, and T. N. Teknos Inhibition of the Growth of Squamous Cell Carcinoma by Tetrathiomolybdate-Induced Copper Suppression in a Murine Model Arch Otolaryngol Head Neck Surg, July 1, 200

A new US study suggests that flaxseed, which is rich in omega 3 fatty acids and lignans, can stop prostate cancer tumours from growing.\n\nThe study was presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on

Anticancer properties of Ganoderma lucidum methanol extracts in vitro and in vivo. Harhaji Trajković LM, Mijatović SA, Maksimović-Ivanić DD, Stojanović ID, Momcilović MB, Tufegdzić SJ, Maksimović VM, Marjanović ZS, Stosić-Grujicić SD. Nutr Cancer. 2009;61(5):696-707. PMID: 19838944 DOI: 10.1080/01635580902898743 Anticancer activities of various extracts of the medicinal mushroom, Ganoderma lucidum, have been widely demonstrated and are mainly associated with the presence of different bioactive polysaccharides and triterpenoids. We have evaluated and compared in vitro and in vivo the antitumor effects of two preparations from Ganoderma lucidum: a methanol extract containing total terpenoids (GLme) and a purified methanol extract containing mainly acidic terpenoids (GLpme). Both extracts inhibited tumor growth of B16 mouse melanoma cells inoculated subcutaneously into syngeneic C57BL/6 mice and reduced viability of B16 cells in vitro, whereby GLme exhibited stronger effect. Furthermore, anticancer activity of GLme was demonstrated for the first time against two other rodent tumor cell lines, L929-mouse fibrosarcoma and C6-rat astrocytoma. The mechanism of antitumor activity of GLme comprised inhibition of cell proliferation and induction of caspase-dependent apoptotic cell death mediated by upregulated p53 and inhibited Bcl-2 expression. Moreover, the antitumor effect of the GLme was associated with intensified production of reactive oxygen species, whereas their neutralization by the antioxidant, N-acetyl cysteine, resulted in partial recovery of cell viability. Thus, our results suggest that GLme might be a good candidate for treatment of diverse forms of cancers.

DURHAM, N.C. -- Restricting carbohydrates, regardless of weight loss, appears to slow the growth of prostate tumors, according to an animal study being published this week by researchers in the Duke Prostate Center. "Previous work here and elsewhere has shown that a diet light in carbohydrates could slow tumor growth, but the animals in those studies also lost weight, and because we know that weight loss can restrict the amount of energy feeding tumors, we weren't able to tell just how big an impact the pure carbohydrate restriction was having, until now," said Stephen Freedland, M.D., a urologist in the Duke Prostate Center and lead investigator on this study. The researchers believe that insulin and insulin-like growth factor contribute to the growth and proliferation of prostate cancer, and that a diet devoid of carbohydrates lowers serum insulin levels in the bodies of the mice, thereby slowing tumor growth, Freedland said.

Fighting cancer with oncolytic viruses. Chernajovsky Y, Layward L, Lemoine N. BMJ. 2006 Jan 21;332(7534):170-2. Review. . PMID: 16424499

Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ, Yang J, Watkins DN, Rudin CM, Hallenbeck PL. J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33. Epub 2007 Oct 30. PMID: 17971529 doi:10.1093/jnci/djm198

Arginine deprivation as a targeted therapy for cancer. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N. Curr Pharm Des. 2008;14(11):1049-57. Review. PMID: 18473854

Phase I Study of White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Women Who Are Breast Cancer Survivors. This is a dose-escalation study. Patients receive oral white button mushroom extract twice daily for 12 weeks in the absence of a second primary ductal carcinoma in situ, invasive breast cancer, or unacceptable toxicity.ble toxicity.\n

The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. Anticancer Res. 2009 Sep;29(9):3511-36. Review. PMID: 19667145 CONCLUSION: Significant associations with VDR polymorphisms have been reported in cancer of the breast (Fok1, Bsm1, Taq1, Apa1, poly (A)), prostate (Fok1, Bsm1, Taq1, poly (A)), skin (Fok1, Bsm1, A-1210), colorectum (Fok1, Bsm1), ovary (Fok1, Apa1) and bladder (Fok1), and in renal cell carcinoma (Taq1, Apa1). However, conflicting data have been reported for most malignancies. After careful evaluation of the actual literature, it can be summarized that data indicating an association of VDR polymorphisms and cancer risk are strongest for breast cancer (Bsm1, Fok1), prostate cancer (Fok1) and malignant melanoma (MM) (Fok1). Data indicating an association of VDR polymorphisms and cancer prognosis are strongest for prostate cancer (Fok1), breast cancer (Bsm1, Taq1), MM (Bsm1) and renal cell carcinoma (Taq1).

Calcium, dairy foods, vitamin D, and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Mizoue T, Kimura Y, Toyomura K, Nagano J, Kono S, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Yasunami Y, Maekawa T, Takenaka K, Ichimiya H, Imaizumi N. Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2800-7. PMID: 18843026

Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Aliment Pharmacol Ther. 2009 Jul 1;30(2):113-25. Epub 2009 Apr 15. PMID: 19392870 DOI: 10.1111/j.1365-2036.2009.04022.x Conclusions Our results support suggestions that serum 25(OH)D is inversely related to CRC risk.

Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. J Clin Oncol. 2009 Aug 10;27(23):3757-63. Epub 2009 May 18. PMID: 19451439 DOI: 10.1200/JCO.2008.20.0725 Conclusion Vitamin D deficiency may be associated with poor outcomes in breast cancer.

Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Tang JY, Parimi N, Wu A, John Boscardin W, Shikany JM, Chren MM, Cummings SR, Epstein EH Jr, Bauer DC; for the Osteoporotic Fractures in Men (MrOS) Study Group. Cancer Causes Control. 2009 Nov 18. [Epub ahead of print] PMID: 19921445 Our results suggest that a diagnosis of NMSC is not a surrogate for adequate 25(OH)D levels or increased UV exposure, and high 25(OH)D levels may be associated with a reduced risk of NMSC.

Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. J Ethnopharmacol. 2009 Oct 29;126(1):5-17. Epub 2009 Aug 15. PMID: 19686830 doi:10.1016/j.jep.2009.08.009 Conclusions The modern evidences of treating cancer with Huanglian and berberine have a strong linkage with traditional concept and rules of using Huanglian in CM practice. As anticancer candidates with low toxicity, berberine and its altered structure, as well as Huanglian and its formulae, will attract scientists to pursue the potential anticancer effects and the mechanisms by using technologies of genomics, proteomics and other advanced approaches. On the other hand, relatively few in vivo studies have been conducted on anticancer effects of Huanglian and berberine. The clinical application of berberine or Huanglian as novel cancer therapeutic agents requires in vivo validations and further investigations of their anticancer mechanisms.

n international consortium led by Baylor College of Medicine and The University of Texas M.D. Anderson Cancer Center has narrowed the search for the gene or genes associated with inherited susceptibility to glioma, a deadly form of brain Cancer, to a region on chromosome 17.